Medidata Solutions Honored in Inc. Magazine’s List of Fastest-Growing Private Companies
FOR IMMEDIATE RELEASE
Medidata Solutions Honored in Inc. Magazine’s
List of Fastest-Growing Private Companies
Leading Clinical Trial Technology Company Noted for Impressive Growth and Performance
NEW YORK, NY – September 5, 2007 – Medidata Solutions today announced its recent recognition in Inc. magazine’s first-ever Inc. 5,000 list of the fastest-growing private companies in the United States. A global provider of electronic clinical data capture (EDC), management and reporting solutions, Medidata Solutions placed 13th in the Inc. 5,000 New York, New Jersey and Long Island region, 14th in the Inc. 5,000 software industry category and 173rd in the overall Inc. 5,000 with a three-year growth rate of 1,193.4 percent.
Medidata’s inclusion in the ranking has been highlighted in the September issue of Inc. magazine, which attributes the company’s expansion to the growing adoption of the Medidata Rave® software solution within the pharmaceutical industry. Medidata Rave enables life sciences companies to electronically collect, manage and report on data from clinical studies of drugs and medical devices to increase the efficiency and safety of bringing life-enhancing treatments to market.
“Our consistent high growth for each of the past three years and key placement in Inc.’s ranking is a result of our increased customer relationships with life sciences companies of all sizes, successful partnerships with leading technology and services providers and strength of our management and professional teams,” said Tarek Sherif, CEO of Medidata Solutions. “We expect sustained momentum for the company as Medidata Rave continues to be viewed as the gold standard of clinical trial technology for biopharmaceutical and medical device companies around the world.”
The 2007 Inc. 5,000 list measures revenue growth from 2003 through 2006 and reported median revenue of $9.4 million and median three-year growth of 140 percent. To qualify, companies had to be U.S.-based and privately held, independent—not subsidiaries or divisions of other companies—as of December 31, 2006, and had at least $200,000 in revenue in 2003 and two million dollars in 2006. Complete information on this year’s Inc. 5,000, can be found at www.inc.com/inc5000.
The health industry reported the third-highest total revenue in 2006 with $13.1 billion, following construction ($27.1 billion) and manufacturing ($18.6 billion) and leading computers and electronics ($12.7 billion) and financial services ($11.8 billion).
“The Inc. 5,000 provides the most comprehensive look ever at the most important part of the economy—the entrepreneurial part,” said Inc. 5,000 Project Manager Jim Melloan. “The expansion of the list has allowed us to tell the stories of larger companies, older companies and a wealth of companies in industries like manufacturing and construction that are underreported in the business media.”
About Inc.com
Inc.com, the Daily Resource for Entrepreneurs, delivers advice, tools, breaking news, and rich multi-media to help business owners and CEOs start, run, and grow their businesses more successfully. Information and advice covering virtually every business and management task, including marketing, sales, finding capital, managing people can be found at http://www.inc.com.
About Medidata Solutions Worldwide
Medidata Solutions helps the world’s leading pharmaceutical, biotechnology, medical device and research organizations maximize the value of their clinical research investments. Innovative process design, technology and services streamline clinical trials by providing early visibility to reliable clinical data—the lifeblood of every research organization. Working with companies and institutions both large and small, Medidata Solutions helps clinical researchers safely accelerate the process of bringing life-enhancing treatments to market—on six continents and in more than 80 countries. Medidata Solutions brings significant value to its broad client base with deep clinical experience and expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. For more information, please visit www.mdsol.com.
Contact:
Susan Lombardo
Lois Paul & Partners
781.782.5767
Susan_Lombardo@lpp.com